Bernstein Upgrades J&J (JNJ) to Outperform; Sees Pharma Pipeline Adding $6B in Sales by 2015

Article Stock Quotes (1) Comments (0)

Bernstein's Derrick Sung upgraded shares of Johnson & Johnson (NYSE: JNJ) from Market Perform to Outperform Wednesday morning. The analyst also boosted Bernstein's price target on the stock by 24 percent from $63 to $78.

The analyst believes Johnson & Johnson's Pharma pipeline is attractive and starting to contribute to sales. Sung argues the unit could eventual drive $6 billion in new product sales by 2015.

Shares of Johnson & Johnson are up 0.5 percent to $66.13 this morning. Bernstein's new price target implies potential upside of nearly 18 percent from where the stock is trading Wednesday.

For more ratings news on Johnson & Johnson click here and for the rating history of Johnson & Johnson click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
• Cowen Upgrades SunPower (SPWR) to Outperform
• Citi Upgrades Gap, Inc. (GPS) to Buy

Create E-mail Alert Related Categories

Hot Upgrades, Upgrades

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?